Alvotech Strikes Long-Term U.S. Manufacturing Pact With LOTTE Biologics to Boost Biosimilar Supply
TipRanks (Wed, 7-Oct 10:47 AM ET)
Alvotech taps LOTTE Biologics to support growing biosimilar portfolio
Seeking Alpha News (Tue, 6-Oct 4:53 PM ET)
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Globe Newswire (Tue, 6-Oct 4:36 PM ET)
ALVO Rallies After FDA Clears a Second Reykjavik Suite for SIMLANDI U.S. Supply
Market Chameleon (Mon, 5-Oct 6:30 AM ET)
Alvotech Wins FDA Nod to Double U.S. Manufacturing Capacity for Humira Biosimilar SIMLANDI
TipRanks (Mon, 5-Oct 8:17 AM ET)
FDA approves additional U.S. manufacturing capacity for Simlandi, Alvotech’s biosimilar to Humira
Seeking Alpha News (Mon, 5-Oct 7:44 AM ET)
At a glance: stocks gapping up premarket
Seeking Alpha News (Mon, 5-Oct 6:52 AM ET)
FDA approves additional U.S. manufacturing capacity for SIMLANDI, Alvotech's biosimilar to Humira
Globe Newswire (Mon, 5-Oct 4:00 AM ET)
Globe Newswire (Mon, 31-Aug 4:30 AM ET)
Alvotech to present at upcoming investor conferences in September
Globe Newswire (Thu, 27-Aug 8:00 AM ET)
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Alvotech - trades on the NASDAQ stock market under the symbol ALVO.
As of October 7, 2026, ALVO stock price declined to $6.12 with 247,657 million shares trading.
ALVO has a beta of 0.96, meaning it tends to be less sensitive to market movements. ALVO has a correlation of 0.03 to the broad based SPY ETF.
ALVO has a market cap of $2.07 billion. This is considered a Mid Cap stock.
Last quarter Alvotech - reported $106 million in Revenue and -$.17 earnings per share. This beat revenue expectation by $545,824 and missed earnings estimates by -$.09.
In the last 3 years, ALVO traded as high as $18.00 and as low as $2.94.
The top ETF exchange traded funds that ALVO belongs to (by Net Assets): IBB, IDNA, EWX, PRFZ, IBBQ.
ALVO has underperformed the market in the last year with a return of -28.7%, while SPY returned +16.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ALVO shares. However, ALVO has outperformed the market in the last 3 month and 2 week periods, returning +76.9% and +4.8%, while SPY returned +3.3% and +0.1%, respectively. This indicates ALVO has been having a stronger performance recently.
ALVO support price is $5.87 and resistance is $6.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALVO shares will trade within this expected range on the day.
